Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Identification Trial for Erlotinib (Tarceva) in Advanced Pancreatic Cancer
2007-003738-40Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in pancreatic cancer (PC) and Pancreatic neoplasia, sponsored by Roche. Primary endpoints: Progression-free survival and Biomarker identification. Started Mar 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)Pancreatic neoplasia
Beyond the preview
Go deeper on 2007-003738-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003738-40.